| dc.creator |
EREN, Ibrahim |
|
| dc.creator |
DEMİRDAŞ, Arif |
|
| dc.creator |
Inanli, Ikbal Civi |
|
| dc.date |
2014-02-28T22:00:00Z |
|
| dc.date.accessioned |
2020-10-06T09:24:44Z |
|
| dc.date.available |
2020-10-06T09:24:44Z |
|
| dc.identifier |
0dc78619-688a-40a6-9df9-7f7f2f7d1fe6 |
|
| dc.identifier |
10.5455/bcp.20130313045200 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/0dc78619-688a-40a6-9df9-7f7f2f7d1fe6/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/53238 |
|
| dc.description |
Introduction: Aripiprazole is a partial agonist of dopamine D-2 and D-3 and serotonin 5-HT1A, 5-HT2c and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D-2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Evaluating The Antidepressant Efficacy of Aripiprazole Using a Chronic Mild Stress Model: An Experimental Study |
|
| dc.type |
info:eu-repo/semantics/article |
|